AIM-listed Allergy Therapeutics has announced a period of strong financial and operational progress in interim results announced today, with market share gains in the European market and progress made towards breaking the $2bn US market.

CEO Manuel Llobet, CFO Nick Wykeman and Head of Comms Alan Bullimore outline the key points of the results in the short film below